Close Menu

Europe

Researchers tested the combined PGS and PGD assay in a pilot study and now aim to validate it on larger numbers of disorders and compare it to conventional testing.

QuantuMDx and Molbio Diagnostics said this week they have signed a memorandum of understanding to work jointly in infectious disease diagnostics.

A GWAS meta-analysis involving 10,074 PCOS cases revealed three new and 11 known risk loci, along with a relatively consistent genetic architecture among cases.

In Science this week: single-cell tools named Breakthrough of the Year winner, differences in gut microbiome composition and function in people with bowel disease, and more.

The government has also pledged €5 million from the European Regional Development Fund to support the integration of genetic data into routine medical care.

The newly launched RT-PCR-based molecular diagnostic kits are designed for use in monitoring post-transplantation and immunosuppressed patients.

The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.

In Nature this week: extension to uncultivated virus genome reporting standards, multiplex orthogonal CRISPR-based genome editing approach, and more.

The test measures hepatitis B viral DNA and is intended to be used to assess prognosis and response to antiviral therapies.

With this latest financing round, the Cambridge, UK-based developer of genomic data management software has raised a total of $3.2 million to date.

Pages

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.